RecruitingPhase 2NCT06241781
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer
Sponsor
Grit Biotechnology
Enrollment
83 participants
Start Date
Apr 2, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years
Inclusion Criteria8
- \. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) ,must have the ability to understand the requirements of the study);
- \. The patient must be 18 to 70 years of age at the time of consent;
- \. Must have a confirmed diagnosis of malignancy of their receptive histologies or cytology: unresectable recurrent or metastatic cervical carcinomas and previously received≥ 1 prior systemic therapy;
- \. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- \. Expected survival time of ≥ 12 weeks;
- \. Adequate normal organ and marrow function;
- \. Before tumor resection, the confirmatory imaging of disease progress since last treatment should be documented.
- Patients must have measurable disease measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (in addition to the resected lesion).
Exclusion Criteria5
- Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring painkiller must already have had a stable pain management options at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;
- Patients who have psychiatric disorders, alcohol, drug or substance abuse;
- Women who are pregnant or breastfeeding, or planning to become pregnant within 1 year after cell infusion;
- Participate in other clinical trials within 4 weeks prior to screening, or planning to participate in this study and other clinical trials at the same time;
- Any other conditions that would make the patient unsuitable candidate for the study at the discretion of the investigator.
Interventions
BIOLOGICALGT101 injection
GT101 injection to treat cervical cancer
DRUGGemcitabine injection
Gemcitabine injection to treat cervical cancer
Locations(24)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06241781
Related Trials
Efficacy of Indonesian Asthmatic Gymnastic as Combine Pulmonary Rehabilitation Based on Asthma Classification
NCT074806161 location
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
NCT071732052 locations
Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes
NCT067356511 location
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
NCT070185181 location
Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure
NCT067355991 location